Disease Overview：Tumor Immunotherapy（CIT）
Immunotherapy for cancer represents a paradigm shift in oncology, leveraging the body’s own immune system to recognize and eliminate malignant cells. Unlike conventional treatments such as chemotherapy or radiation—which broadly target rapidly dividing cells—immunotherapies like immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 agents), CAR-T cell therapy, cancer vaccines, and cytokine-based regimens aim to overcome tumor-induced immunosuppression and restore durable antitumor immunity. This approach has demonstrated remarkable efficacy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, lymphomas, and certain gastrointestinal malignancies, with some patients achieving long-term remission or functional cure. Response is highly individualized, dependent on biomarkers such as PD-L1 expression, tumor mutational burden, and microsatellite instability status. While not universally effective—and associated with unique immune-related adverse events—immunotherapy is increasingly integrated into multimodal treatment strategies, including neoadjuvant, adjuvant, and combination regimens.
China has emerged as a leading destination for immunotherapy due to its robust clinical research infrastructure, rapid regulatory approval of novel agents—including domestically developed PD-1 inhibitors approved by the NMPA—and widespread access to next-generation sequencing, liquid biopsy, and flow cytometry–guided cellular therapies. Leading academic hospitals such as Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center report high response rates in real-world cohorts, particularly in NSCLC and hepatocellular carcinoma. Treatment costs are typically 40–60% lower than in the U.S. or Western Europe, without compromising quality—many centers participate in global phase III trials and adhere to NCCN/ESMO guidelines. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: coordinating appointments with certified oncologists, verifying hospital accreditation and treatment protocols, providing itemized, transparent pricing in advance, and offering end-to-end support—from visa assistance and medical translation to post-treatment follow-up coordination.
Tumor Immunotherapy: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Tumor Immunotherapy (Oncology Department)
Non-Surgical / Medication-Based Immunotherapies
*Eligibility*: Confirmed solid or hematologic malignancy with PD-L1 expression ≥1% (IHC), MSI-H/dMMR status, or specific biomarker eligibility (e.g., NTRK fusion); ECOG PS ≤2; adequate organ function.
- •PD-1/PD-L1 Inhibitors (e.g., Pembrolizumab, Camrelizumab, Sintilimab)
- *Baseline biomarker testing (PD-L1 IHC + MSI/MMR PCR)*: $240 - *Monthly labs (CBC, LFTs, TSH, cortisol)*: $65/cycle - *CT/MRI surveillance (q8–12 weeks)*: $420–$580/study
- •CTLA-4 + PD-1 Dual Checkpoint Blockade (e.g., Ipilimumab + Nivolumab)
- *Maintenance PD-1 monotherapy (q4w)*: $2,100–$3,400/cycle - *Autoimmune toxicity monitoring (adrenal panel, stool calprotectin, colonoscopy if colitis suspected)*: $180–$390 per episode
Surgical/Procedural/Interventional Immunotherapy Support
*Eligibility*: Resectable tumor with high immunogenic potential (e.g., melanoma, RCC, NSCLC stage IB–IIIA); no contraindications to surgery or perioperative immunotherapy.
- •Neoadjuvant Immunotherapy (pre-op, 2–4 cycles)
- *Preoperative workup (EKG, pulmonary function, enhanced CT/PET-CT, cardiac echo if indicated)*: $1,150–$1,720
- •Adjuvant Immunotherapy (post-op, up to 1 year)
- *Surgical pathology review + tumor mutational burden (TMB) assay*: $310
Special/Complex Condition Options
- •CAR-T Therapy (for relapsed/refractory B-cell lymphoma or multiple myeloma)
- *Pre-CAR-T lymphodepletion (Fludarabine/Cyclophosphamide)*: $1,450 - *ICANS/CRS management (tocilizumab, corticosteroids, ICU support)*: $3,200–$9,800
- •Tumor-Infiltrating Lymphocytemelanoma, cervical cancer – investigational but clinically available at select centers)
- •<60 years, fit, high-risk resectable NSCLC: Neoadjuvant nivolumab + surgery ($10,200–$16,300 total) — optimal balance of efficacy and cost.
- •Age 75+, limitedCLC PD-L1 ≥50%: Single-agent camrelizumab ($1,850/cycle; $22,200/year) — lower toxicity, predictable cost.
- •Relapsed DLBCL after 2 lines: CAR-T ($128,000+) — only curative option; requires ≥$100K budget or insurance coverage.
- •MSI-H colorectal cancer, multiple comorbidities: Pembrolizumab monotherapy ($2,900/cycle) — avoids chemo toxicity, lowest monitoring burden.
- •Severe autoimmune disease (e.g., active RA, IBD): Avoid CTLA-4; use PD-1 inhibitor + rigorous rheumatology co-management (+$480/month consult fee).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Tumor Immunotherapy Medical Vacation Packages
Curated transparent all-inclusive packages combining Tumor Immunotherapy treatment with China top medical destinations:
